Table 1.
Baseline characteristics.
| Characteristics Malignant Group |
Study Group,
Malignant n = 115 |
Test Group,
Malignant n = 40 |
Differences between
Malignant Groups, p-Value |
Differences
between Test Group and Study Group in Total p-Values |
| Gender | - | - | 0.72 | 0.88 |
| Male (%) | 67 (58.2) | 22 (55.0) | - | - |
| Female (%) | 48 (41.7) | 18 (45.0) | - | - |
| Age median (range) | 14.0 (1–18) | 14.2 (2–18) | 0.53 | 0.80 |
| Diagnoses (%) | - | - | 0.26 | - |
| Hodgkin lymphoma | 90 (78.3) | 29 (72.5) | - | - |
| cHL | 79 | 26 | - | - |
| NLPHL | 11 | 3 | - | - |
| Non-Hodgkin lymphoma | 24 (20.9) | 11 (27.5) | - | - |
| ALCL | 5 | 1 | - | - |
| PMBCL | 1 | 0 | - | - |
| DLBCL | 3 | 1 | - | - |
| BL | 5 | 0 | - | - |
| T-LBL | 8 | 9 | - | - |
| B-LBL | 2 | 0 | - | - |
| Other malignancy | 1 (0.9) | 0 (0.0) | - | - |
| Histiocytosis | 1 | 0 | - | - |
| Isolated lymphadenopathy (%) * | 8 (6.9) | 3 (7.5) | 0.91 | 1.00 |
| cHL | - | 1 | - | - |
| NLPHL | 8 | 2 | - | - |
| Characteristics Benign Group |
Study Group,
Benign n = 67 |
Test Group,
Benign n = 20 |
Differences between
Benign Groups, p-Value |
Not Applicable |
| Gender | - | 0.95 | - | |
| Male (%) | 33 (49.3) | 10 (50.0) | - | - |
| Female (%) | 34 (50.7) | 10 (50.0) | - | - |
| Age median (range) | 12.5 (0–17) | 13.5 (1–18) | 0.51 | - |
| Diagnoses (%) | - | 0.19 | - | |
| Reactive/infective lymphadenopathy | 48 | 15 | - | - |
| Immunological disorder | 5 | 2 | - | - |
| PTGC | 4 | 2 | - | - |
| Morbus Castleman | 2 | - | - | - |
| Rheumatological disorder | 2 | - | - | - |
| Ruptured branchiogenic cyst | 3 | - | - | - |
| Venous malformation | 1 | 1 | - | - |
| Lymphangioma | 1 | - | - | - |
| Dermoid cysts | 1 | - | - | - |
| Isolated lymphadenopathy (%) * | 21 (31.3) | 6 (30.0) | 0.91 | - |
| Reactive/infective lymphadenopathy | 13 | 5 | - | - |
| PTGC | 1 | - | - | - |
| Morbus Castleman | 1 | - | - | - |
| Ruptured branchiogenic cyst | 3 | - | - | - |
| Venous malformation | 1 | 1 | - | - |
| Lymphangioma | 1 | - | - | - |
| Dermoid cysts | 1 | - | - | - |
Table 1 describes the baseline characteristics of the malignant and benign group separately. Furthermore, differences between the different groups were investigated We calculated whether the input variable distribution was significantly different between the study and test cohort, for the whole set combined, and for the malignant and benign cases separately. Abbreviations: NA—not applicable; cHL—classical Hodgkin lymphoma; NLPHL—nodular lymphocyte-predominant Hodgkin lymphoma; ALCL—anaplastic large cell lymphoma; PMBCL—primary mediastinal large B-cell lymphoma; DLBCL—diffuse large B-cell lymphoma; BL—Burkitt lymphoma; T-LBL—T-cell lymphoblastic lymphoma; B-LBL—B-cell lymphoblastic lymphoma; PTGC—progressive transformation of germinal centers. * Isolated lymphadenopathy is defined as only one or two lymph nodes involved.